← Back to Search

Iodide Supplement

SSKI (Potassium Iodide) for Graves Disease

Phase 3
Waitlist Available
Led By Jennifer Kuo, MD
Research Sponsored by Columbia University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline to immediately before surgery
Awards & highlights

Summary

This trial is testing if SSKI, a type of iodine, can reduce blood vessels in the thyroid and lower bleeding risks for patients with Graves' disease who need their thyroid removed. SSKI has been used to help prepare patients for surgery in difficult cases of Graves' disease.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline to immediately before surgery
This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline to immediately before surgery for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Vascular Flow from Baseline

Trial Design

2Treatment groups
Active Control
Group I: SSKI (Potassium Iodide)Active Control1 Intervention
Participants randomized to receive 7 days of pre-operative SSKI
Group II: NO SSKIActive Control1 Intervention
Participants randomized to not receive any drug pre-operative

Find a Location

Who is running the clinical trial?

Columbia UniversityLead Sponsor
1,471 Previous Clinical Trials
2,536,321 Total Patients Enrolled
Jennifer Kuo, MDPrincipal Investigator - Columbia University
Hudson Valley Hospital Center, New York Presbyterian Hospital-Allen Hospital, The, New York Presbyterian Hospital-Columbia Presbyterian Center, New York Presbyterian Hospital/Weill Cornell Medical Center, NewYork-Presbyterian/Lawrence Hospital
Columbia University College Of Physicians And Surgeons (Medical School)
~3 spots leftby Sep 2025